Microbiologics takes over Sensid: Revolution in diagnostics!

Microbiologics takes over Sensid: Revolution in diagnostics!

Rostock, Deutschland - Saint Cloud, Minnesota (ots/Prnewswire)

In an impressive merger in the medical sector, Microbiologics takes the reins in hand and takes over Sensid, an innovator in molecular diagnostics! Sensid, founded in Rostock, Germany in 2015, will bundle the forces as a new player in the Microbiologics team to raise the diagnosis of infectious diseases and oncology to a completely new level. This strategic acquisition marks Microbiologics' first step outside the United States and promises an exciting future for both companies.

The takeover is a strategic step for Microbiologics, which is now also focusing on precision medicine and oncology. The concentrated expertise of both companies will help to develop a more comprehensive portfolio of quality control solutions. "This partnership has an immense importance for us. It is not just about expanding our technological capacities, but rather about the common vision of shaping the future of diagnostics and improving patient welfare worldwide," explains Kristen Knox, CEO from Microbiologics.

Cancer diagnostics in focus

Sensid is known for his tireless use in oncology, which has revolutionized the industry with precisely characterized reference materials. The latest innovations, such as the ESR1 mutation reference set, which supports the validation of cell-free DNA detection procedures, are amazing! "This merger is a natural choice! Together we can further expand our innovative approaches," says Björn Nowack, CEO of Sensid.

Despite the growing structures, both companies assure that the usual product and service quality remains maintained. While Microbiologics shines in the diagnosis of infectious diseases, Sensids will exceed excellent expertise in molecular oncology that has been there so far! The future of diagnostic quality control has just started! How will this merger affect medical care? Only time will show it!